Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

Though prescribing climate-friendly dry powder inhalers is environmentally sound, some experts warn certain patients may be ...

GSK has become the first founding partner of the new Fleming Initiative, which aims to tackle the rising threat of antimicrobial resistance (AMR) and is also backed by the UK government.

From healthcare to banking, it is the software-of-choice for some of the biggest names in the UK market. Think AstraZeneca (AZN.L), GSK (GSK.L), Rolls-Royce (RR.L) and Lloyds (LLOY.L). Even the London ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

A new generic version of varenicline – originally sold in the UK as Champix by Pfizer – has now been approved for use by the ...

By restructuring our collaboration with GSK, we have embarked on a new chapter of growth and ... as well as co-heading European healthcare investments at 3i Group plc, a UK-listed private equity firm ...

The drugmaker’s U.S. plans comes on the heels of a rough quarter, with lower vaccine demand driving down Q3 sales by 15% year ...

The US group's division has reported a pre-tax profit of $39.5m (£30.6m) for the 12 months to 31 January, 2024, according to ...

Harvey Jones thought he was getting a bargain when he snapped up these too much-loved FTSE 100 dividend growth stocks. Now they're getting on his nerves.